FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Pfizer Quillivant XR Recall

Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL…

Pfizer Inc · Peapack, NJ

Risk level
Class III
Reported by FDA
Mar 29, 2017
Recall ID
D-0608-2017
Check your lot numberHow we source this data

Summary

Pfizer recalled Quillivant XR starting Mar 7, 2017. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0608-2017 on Mar 29, 2017. Reason: Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius. Status: Terminated.

Why it was recalled

Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.

Product description

Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017 Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).

Lot numbers, UPCs & expiration codes

Lot #: 03216026A, Exp. 02/18

Where it was sold

Nationwide within US

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0608-2017
Classification
Class III
Status
Terminated
Recall initiated
Mar 7, 2017
FDA report date
Mar 29, 2017
Quantity
11,862 units
Recall type
Voluntary: Firm initiated
Recalling firm
Pfizer Inc

Original FDA data

Every field from FDA enforcement report D-0608-2017, exactly as published.

Show all FDA fields
City
Peapack
State
NJ
Status
Terminated
Country
United States
Event ID
76663
Address
100 North Route 206
Code information
Lot #: 03216026A, Exp. 02/18
Postal code
07977
Report date
Mar 29, 2017
Product type
Drugs
Recall number
D-0608-2017
Classification
Class III
Recalling firm
Pfizer Inc
Product quantity
11,862 units
Termination date
May 31, 2019
Reason for recall
Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017 Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).
Distribution pattern
Nationwide within US
Recall initiation date
Mar 7, 2017
Initial firm notification
Letter
Center classification date
Mar 22, 2017

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0608-2017, published Mar 29, 2017. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls